Advanced Medical Solutions Group plc Stock price
Equities
AMS
GB0004536594
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
196.00 GBX | -0.20% | +5.04% | -24.32% |
Sep. 20 | The clock is ticking... | ![]() |
Sep. 20 | ANALYST RECOMMENDATIONS : Centrica, Chewy, Dollar General, Pearson, Western Digital... | ![]() |
Sales 2023 * | 125 M 152 M | Sales 2024 * | 137 M 167 M | Capitalization | 426 M 517 M |
---|---|---|---|---|---|
Net income 2023 * | 16 M 19 M | Net income 2024 * | 19 M 23 M | EV / Sales 2023 * | 2,89x |
Net cash position 2023 * | 65 M 79 M | Net cash position 2024 * | 77 M 93 M | EV / Sales 2024 * | 2,54x |
P/E ratio 2023 * | 25,1x | P/E ratio 2024 * | 21,3x | Employees | - |
Yield 2023 * | 1,18% | Yield 2024 * | 1,28% | Free-Float | 97.35% |
More Fundamentals
* Assessed data
More news
More recommendations
More news
1 day | -0.20% | ||
1 week | +5.04% | ||
Current month | -23.14% | ||
1 month | -22.22% | ||
3 months | -13.08% | ||
6 months | -12.89% | ||
Current year | -24.32% |
1 week
188.00
202.50

1 month
165.60
261.00

Current year
165.60
289.50

1 year
165.60
304.50

3 years
165.60
347.00

5 years
165.60
357.21

10 years
90.00
374.00

Managers | Title | Age | Since |
---|---|---|---|
Andrew Meredith
CEO | Chief Executive Officer | 57 | 2010 |
Edward Johnson
DFI | Director of Finance/CFO | 51 | 2018 |
Alan Richardson
COO | Chief Operating Officer | - | 2018 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Meredith
BRD | Director/Board Member | 57 | 2010 |
Peter Allen
CHM | Chairman | 67 | 2013 |
Edward Johnson
BRD | Director/Board Member | 51 | 2018 |
Date | Price | Change | Volume |
---|---|---|---|
23-09-27 | 196.00 | -0.20% | 368,411 |
23-09-26 | 196.40 | -0.41% | 513,876 |
23-09-25 | 197.20 | +1.75% | 507,247 |
23-09-22 | 193.80 | +0.62% | 330,295 |
23-09-21 | 192.60 | +3.22% | 478,288 |
Delayed Quote London Stock Exchange, September 27, 2023 at 11:35 am EDT
More quotes
Advanced Medical Solutions Group plc is a United Kingdom-based company that specialize in the design, development, manufacture and distribution of novel tissue-healing technologies, including advanced wound care products, surgical dressings and medical grade materials, as well as medical adhesives and sutures for closing and sealing tissue. The Company manufactures a range of products and materials that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats. It operates through two divisions for its sales, marketing and research and development (R&D) activities, including Surgical and Woundcare. Its surgical business unit is focused on selling and marketing its branded products and are sold directly and through distributors. Its Woundcare business unit is focused on distribution and marketing its products that are supplied to medical device partners under their own brands. The Company offers its products under ActivHeal, LiquiBand and RESORBA.
Calendar
2024-03-12
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
1.960GBP
Average target price
2.551GBP
Spread / Average Target
+30.15%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-24.32% | 519 M $ | |
-33.00% | 526 M $ | |
-5.72% | 529 M $ | |
+7.41% | 464 M $ | |
-4.02% | 461 M $ | |
-13.65% | 435 M $ | |
-21.12% | 647 M $ | |
-0.81% | 650 M $ | |
-0.36% | 660 M $ | |
+24.72% | 335 M $ |